⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Data 1 from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

James Larkin Michele Del Vecchio Mario Mandalà Helen Gogas Ana Arance Stéphane Dalle Charles Lance Cowey Michael Schenker Jean‐Jacques Grob Vanna Chiarion‐Sileni Iván Márquez‐Rodas Marcus O. Butler Anna Maria Di Giacomo Mark R. Middleton Jose Lutzky Luis de la Cruz‐Merino Petr Arenberger Victoria Atkinson Andrew G. Hill Leslie A. Fecher Michael Millward Paul Nathan Nikhil I. Khushalani Paola Queirolo Corey Ritchings Maurice Lobo Margarita Askelson Hao Tang Sonia Dolfi Paolo A. Ascierto Jeffrey S. Weber

View at Publisher

Ask AI

Bookmark

Share

Abstract

DATA SUPPLEMENT Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Larkin et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522e63 https://doi.org/10.1158/1078-0432.27030961

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Data 1 from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 2382024
2Data from Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 2382024
3Data from SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma2024
4Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaLate-Phase Clinical Trial · 2022 · 550 citations
5Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMelLate-Phase Clinical Trial · 2026

More related papers

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial2025
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data2024
Data from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study2024